Grifols (GIFLF) Change in Receivables (2010 - 2025)
Grifols' (GIFLF) quarterly Change in Receivables came in at -$37.2 million in Q4 2025, up 17.0% on a YoY basis from -$31.8 million in Q4 2024, and up 17.0% quarter-over-quarter from -$44.9 million in Q4 2024.
Analysis
Grifols (GIFLF) Change in Receivables (2010 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Change in Receivables for 15 consecutive years, with -$37.2 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Change in Receivables rose 17.0% year-over-year to -$37.2 million; the trailing twelve-month figure through Dec 2025 stood at -$235.4 million (down 19.69% YoY), and the FY2025 full-year result was -$36.2 million, up 19.44% from the prior year.
- Change in Receivables rose to -$37.2 million in Q4 2025 per GIFLF's latest filing, from -$44.9 million in the prior quarter.
- Across five years, Change in Receivables topped out at -$37.2 million in Q4 2025 and bottomed at -$79.1 million in Q4 2022.
- Historically, Change in Receivables has averaged -$58.9 million across 4 years, with a median of -$59.6 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Change in Receivables gained 6.1% in 2023, then soared 39.55% in 2024.
- Over 4 years, Change in Receivables stood at -$79.1 million in 2022, then grew by 6.1% to -$74.2 million in 2023, then jumped by 39.55% to -$44.9 million in 2024, then gained by 17.0% to -$37.2 million in 2025.
- According to Business Quant data, Change in Receivables over the past three periods registered -$37.2 million, -$44.9 million, and -$74.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 1.09 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 333.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 140.20 Mn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 838.50 Mn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | -53.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 269.40 Mn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | -37.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -37.25 Mn |
| Dec 31, 2024 | -44.88 Mn |
| Dec 31, 2023 | -74.24 Mn |
| Dec 31, 2022 | -79.06 Mn |
| Mar 31, 2020 | 1.48 Mn |
| Dec 31, 2019 | -15.12 Mn |
| Mar 31, 2019 | -163.95 Mn |
| Dec 31, 2018 | 16.91 Mn |
| Jun 30, 2018 | -90.04 Mn |
| Mar 31, 2018 | 14.96 Mn |
| Dec 31, 2017 | 81.48 Mn |
| Jun 30, 2017 | -19.98 Mn |
| Mar 31, 2017 | 61.00 Mn |
| Dec 31, 2016 | 3.53 Mn |
| Sep 30, 2016 | 66.00 Mn |
| Dec 31, 2015 | 76.79 Mn |
| Sep 30, 2015 | 26.03 Mn |
| Jun 30, 2015 | 19.33 Mn |
| Mar 31, 2015 | 37.80 Mn |
| Dec 31, 2014 | 57.70 Mn |